Display options
Cite
Ferro M, Chiujdea S, Musi G, et al. Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clin Genitourin Cancer. 2021;doi: 10.1016/j.clgc.2021.12.005.
Ferro, M., Chiujdea, S., Musi, G., Lucarelli, G., Giudice, F. D., Hurle, R., Damiano, R., Cantiello, F., Mari, A., Minervini, A., Busetto, G. M., Carrieri, G., Crocetto, F., Barone, B., Caputo, V. F., Cormio, L., Ditonno, P., Sciarra, A., Terracciano, D., Cioffi, A., Luzzago, S., Piccinelli, M., Mistretta, F. A., Vartolomei, M. D., & de Cobelli, O. (2021). Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clinical genitourinary cancer, . https://doi.org/10.1016/j.clgc.2021.12.005
Ferro, Matteo, et al. "Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis." Clinical genitourinary cancer vol. (2021). doi: https://doi.org/10.1016/j.clgc.2021.12.005
Ferro M, Chiujdea S, Musi G, Lucarelli G, Giudice FD, Hurle R, Damiano R, Cantiello F, Mari A, Minervini A, Busetto GM, Carrieri G, Crocetto F, Barone B, Caputo VF, Cormio L, Ditonno P, Sciarra A, Terracciano D, Cioffi A, Luzzago S, Piccinelli M, Mistretta FA, Vartolomei MD, de Cobelli O. Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clin Genitourin Cancer. 2021 Dec 10; doi: 10.1016/j.clgc.2021.12.005. Epub 2021 Dec 10. PMID: 35033480.
Copy Download .nbib Format: NLM
Share it on

Clin Genitourin Cancer. 2021 Dec 10; doi: 10.1016/j.clgc.2021.12.005. Epub 2021 Dec 10.

Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis.

Clinical genitourinary cancer

Matteo Ferro, Sever Chiujdea, Gennaro Musi, Giuseppe Lucarelli, Francesco Del Giudice, Rodolfo Hurle, Rocco Damiano, Francesco Cantiello, Andrea Mari, Andrea Minervini, Gian Maria Busetto, Giuseppe Carrieri, Felice Crocetto, Biagio Barone, Vincenzo Francesco Caputo, Luigi Cormio, Pasquale Ditonno, Alessandro Sciarra, Daniela Terracciano, Antonio Cioffi, Stefano Luzzago, Mattia Piccinelli, Francesco Alessandro Mistretta, Mihai Dorin Vartolomei, Ottavio de Cobelli

Affiliations

  1. Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy. Electronic address: [email protected].
  2. IOSUD, Universitatea de Medicin? Farmacie, ?tiinte ?i Tehnologie "George Emil Palade" din Târgu Mure?, Mure?, Romania.
  3. Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy; Department of Oncology and Hematology Oncology, Faculty of Medicine and Surgery, University of Milan, Milan, Italy.
  4. Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Italy.
  5. Department of Urology, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
  6. IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
  7. Department of Urology, University of Catanzaro, UNIVERSITÁ "MAGNA GRÆCIA" di Catanzaro, Catanzaro, Italy.
  8. Unit of Oncologic Minimally- Invasive Urology and Andrology, University of Florence, Careggi University Hospital, Florence, Italy.
  9. Department of Urology and Organ Transplantation, University of Foggia, Foggia, Italy.
  10. Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples "Federico II", Naples, Italy.
  11. Department of Urology and Renal Transplantation, University of Foggia-Ospedali Riuniti of Foggia, Foggia, Italy; Department of Urology, Bonomo Teaching Hospital, Andria (BAT), Italy.
  12. Department of Emergency and Organ Transplantation-Urology, Andrology and Kidney Transplantation Unit, University of Bari, Bari, Italy.
  13. Department of Translational Medical Sciences, University of Naples "Federico II", Naples, Italy.
  14. Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy.
  15. Division of Urology, European Institute of Oncology (IEO)-IRCCS, Milan, Italy; IOSUD, Universitatea de Medicin? Farmacie, ?tiinte ?i Tehnologie "George Emil Palade" din Târgu Mure?, Mure?, Romania; Urology Department, Medical University of Vienna, Vienna, Austria.

PMID: 35033480 DOI: 10.1016/j.clgc.2021.12.005

Abstract

INTRODUCTION: The aim of this multicenter study was to investigate the role of age (cut-off 70 years) at diagnosis in predicting oncologic behavior of pure carcinoma in situ of the bladder.

MATERIAL AND METHODS: Inclusion criteria were: patients with pure CIS confirmed and that followed intravesical BCG treatment. Pure CIS was defined at any CIS not associated with another urothelial cancer. Exclusion criteria were: any CIS associated with invasive urothelial carcinoma. A total of 172 with pure CIS treated between January 1, 2002 and December 31, 2012 at 8 academic institutions met the inclusion criteria. The maintenance schedule was generally according to the EAU guidelines at the time RESULTS: A total of 99 (57.6%) patients had an age >70 years prior to TURBT. There was no difference between clinico-pathologic features among groups (group 1, age ≤ 70 years and group 2, age > 70 years), except that patients aged ≤ 70 years presented a larger size of CIS (35.6% vs. 21.2%), P = .02. In multivariable Cox regression analyses, the same clinico-pathologic factors (age, multifocality, and recurrent tumor state) were independently associated with worse RFS. Harrell's C-index was 65.75.In multivariable Cox regression analyses in addition to age (P = .006) and multifocality (P < .001) also BMI (P = .04) was independently associated with worse PFS. Harrell's C-index was 74.71 CONCLUSION: Advanced age at diagnosis appears to be associated with an increased risk of recurrence and progression of pure carcinoma in situ of the bladder. Elderly patients might fail to respond to BCG therapy.

Copyright © 2021 Elsevier Inc. All rights reserved.

Keywords: Aging; Bladder cancer; Oncological outcomes; Progression; Recurrence

Publication Types